Scientists at La Jolla Institute for Immunology (LJI) have discovered that combining key vaccine ingredients could give the body the tools it needs to fight the entire family of arenaviruses with a single vaccine.

Critical Path Institute today announced the launch of the New Approach Methodologies Developer Coalition (NAMs-DC), a precompetitive, public-private initiative bringing together companies that develop new approach methodologies (NAMs) to accelerate their adoption, validation, and qualification as tools for drug discovery and development. The coalition formally launches ahead of the MPS World Summit, which convenes the global microphysiological systems community the week of May 25, 2026.

Healthcare has lost its human, moral, and relational foundations and must reconnect with its core values to improve both patient and staff well-being, argue experts in The BMJ today.

Critical Path Institute® today announced the award of a $249,719 research grant to Odylia Therapeutics, a nonprofit biotechnology organization based in Atlanta. The awarded program and Odylia are led by Ashley Winslow, Ph.D., CEO and Chief Scientific Officer. The award is part of C-Path’s Bridging Research and Innovation in Drug Development Grants (BRIDGe) program, offered through its Translational Therapeutics Accelerator.

When health policy researchers at the Brown University School of Public Health tracked data from primary care practices that had been acquired by private equity firms, they found something surprising: not all of the changes were detrimental. 

A PLOS Medicine analysis led by Fred Hutch Cancer Center researchers quantified the enduring impact that China’s health policies during the COVID-19 pandemic had on overall healthcare utilization. As the first country to report COVID-19 cases and implement infection control measures, and among the last to lift such policies, China’s experience presented a unique opportunity to study the relationship between public health measures and healthcare access.